
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Studies to date have revealed interesting findings in the structure aInd function of healthy infant skin and how those features change during infancy. This research may lead to the development of better infant skincare products.